Drug Access Standards
Drug Access Standards - Related Videos
14:37
Accessibility to Clinical Care for People who use Wheelchairs
0 Views •
2023
Source: Yetsa Tuakli-Wosornu1,2, Jaideep Talwalkar1; 1Yale School of Medicine, 2University of Pittsburgh In the United States, 25% of the general population suffers from one or another type of disability. Ambulatory disabilities, or mobility impairments, represent the most common subcategory, comprising 14% of the country's populace. Different mobility-assistive devices, ranging from canes to scooters, enable increased independence and improved quality of life for those suffering from mobility...
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
0 Views •
Cited by 4 •
2016
Here we describe a protocol using the web-based drug repurposing hypothesis generation tool: "RE:fine Drugs." This protocol can be modified to a user's preferences at the level of the query type (gene, drug or disease) and/or the range of available advanced options.
11:56
Central Venous Access Device Dressing Change
0 Views •
2023
Source: Madeline Lassche, MSNEd, RN and Katie Baraki, MSN, RN, College of Nursing, University of Utah, UT Central venous access devices (CVAD), commonly known as central lines or central catheters, are large-bore intravenous (IV) catheters that are introduced into the central circulation. Typically, CVADs terminate in the superior vena cava, just outside of the right atrium of the heart, but they may also terminate in any one of the great veins (i.e., aorta, inferior vena cava, brachiocephalic...
07:22
Standardized Method for Measuring Collection Efficiency from Wipe-sampling of Trace Explosives
0 Views •
Cited by 7 •
2017
Optimized sampling protocols and the development of new wipe materials can be facilitated by standardized measurements of collection efficiency from wipe-sampling. Our approach for sampling trace explosives uses an automated device to control speed, force, and distance during wipe-sampling followed by extraction of collected explosives.
09:18
Internal Standards
0 Views •
2023
Source: Laboratory of Dr. B. Jill Venton - University of Virginia The goal of many chemical analyses is a quantitative analysis, where the amount of a substance in a sample is determined. In order to accurately calculate the concentration of an unknown from a sample, careful sample preparation is key. Every time a sample is handled or transferred, some of the sample can be lost. There are strategies however, for minimizing sample loss. There are also strategies for coping with sample loss and...
FAQs
They provide a structured basis for weighing a patient’s clinical needs against broader concerns about safety, evidence, supply, and responsible resource allocation. This approach helps reduce inconsistent decisions while allowing access pathways to reflect both individual circumstances and population-level priorities. In practice, standards support decisions that are more consistent, transparent, and clinically responsible.
These criteria address different conditions required for appropriate medicine access. Quality concerns whether the medicine meets expected standards, while safety and efficacy relate to potential risks and clinical benefit. Eligibility identifies who may receive it, and supply affects whether access can be maintained. Considering them together creates a more complete basis for clinical and regulatory decisions.
New therapies, emerging evidence, and changing delivery models can alter how medicines should be evaluated, supplied, or monitored. Standards therefore need continued refinement rather than remaining fixed. Updating them helps clinical and regulatory processes respond to new information while preserving attention to safety, efficacy, equitable access, and appropriate use.
They help guide judgments about which medicines should be available within a clinical formulary and under what conditions. Decision makers can use evidence on quality, safety, efficacy, eligibility, and supply to support responsible resource allocation. Applying consistent criteria can also reduce variation in formulary decisions and clarify how patient needs are considered.
Access can be organized as a linked pathway: authorization establishes whether use is permitted, prescribing applies the medicine to an eligible clinical situation, distribution makes the treatment available, and monitoring supports continued oversight. Coordinating these stages helps ensure that access is not treated as a single decision but as a process requiring appropriate management across care.
They are particularly relevant when participation or treatment depends on defined eligibility, authorization, controlled distribution, or additional monitoring. In clinical trials, standards can help structure access and participation decisions. For medicines requiring special oversight, they support consistent pathways that address patient suitability, safe use, supply, and follow-up within the clinical setting.